

VIA HAND DELIVERY DECEMBER 19, 2001  
*#34/PK*IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Hastings et al.

Attorney Docket No.: PF147D1

Application Serial No.: 09/037,460

Art Unit: 1647

Filed: March 10, 1998

Examiner: Saoud, C.

Title: Human Vascular IBP-Like Growth Factor  
Polynucleotides (as amended)REQUEST FOR CORRECTION OF FILING RECEIPTCommissioner for Patents  
Washington, D.C. 20231Attn: Office of Initial Patent Examination  
Customer Service Center

Sir:

Applicants hereby request that a Corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically,

1. Under Domestic Priority Data as claimed by applicant, please add  
--WHICH IS A CIP OF PCT/US94/14388 12/09/1994
2. Under Foreign Applications, please delete --PCT/US94/14388 12/09/1994--.

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the correction noted in red. It is requested that a Corrected Official Filing Receipt be issued and sent to the undersigned at the earliest possible time.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3425.

Respectfully submitted,

Date: December 19, 2001

  
Jonathan L. Klein Reg. No. 41,119  
Attorney for Applicants

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, MD 20850  
Phone: (301) 251-6015

JKE/CCB/ba



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILED DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/037,460	03/10/1998	1647	7900	325800-626 (P)	6	32	4

CONFIRMATION NO. 7163

CORRECTED FILING RECEIPT

[REDACTED]  
OC0000000008525353

22195  
 HUMAN GENOME SCIENCES INC  
 9410 KEY WEST AVENUE  
 ROCKVILLE, MD 20850

JKE CB

Date Mailed. 09/07/2001

Receipt is acknowledged of a CPA in this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

GREGG A. HASTINGS, ROCKVILLE, MD.  
 CRAIG A. ROSEN, LAYTONSVILLE, MD;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 08/464,339 06/05/1995 PAT 5,747,280

WHICH IS A C1P OF PCT/US94/14388 12/09/1994

## Foreign Applications

PCT/US94/14388 12/09/1994

If Required, Foreign Filing License Granted 04/01/1998

CPA filed on: 07/16/2001

Projected Publication Date: 12/13/2001

Non-Publication Request: No

Early Publication Request: No

## Title

HUMAN VASCULAR IBP-LIKE GROWTH FACTOR

BEST AVAILABLE COPY

May-07-02 02:27pm From-HGS PATENT DEPT

3013098439

T-236 P.15/17 F-114

Preliminary Class

435

---

Data entry by : TRAMMELL, GLORIA

Team : 1600

Date: 09/07/2001



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

**BEST AVAILABLE COPY**

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231